Skip to main content

Q&A with the Portfolio Manager: Global Healthcare Equities

24 August 2023

Steven Slaughter, Lead Portfolio Manager

CJ Sylvester, Portfolio Manager

COVID-19 is largely behind us in terms of a global health crisis and a hard hit to global financial markets. Yet, amid a widely predicted economic recession, the world is adjusting to the post-pandemic era. In this Q&A, Steven Slaughter, Lead Portfolio Manager, and CJ Sylvester, Portfolio Manager, highlight how our Global Healthcare Team adopts a differentiated approach by triangulating its investment thesis and quantifying key inputs into the investment framework.

1. Although COVID-19 is largely behind us, market concerns about a looming economic recession linger. Can you illustrate the defensiveness of this sector and its sub-sectors during previous market downturns?

As the Macroeconomic Strategy Team highlighted in its Global Macro Outlook Q3 2023, the recession has been postponed, not cancelled. Market concerns about a U.S. economic recession will likely be carried over to the second half of this year.

As our investors know, the healthcare sector remains one of the most recession-resistant areas of the economy. It has been a defensive stalwart during enhanced volatility and economic uncertainty. In particular, the outperformance of healthcare in recent economic downturns was primarily due to inelastic demand for medical resources.

During the most recent recessionary periods, sub-sector dispersion was wide. Pharmaceuticals generally provided good, sometimes better, protection, while biotech outperformed in three out of the recent four market downturns. Also, healthcare providers & services witnessed increased returns in the last three recessions. (Refer to Chart 1).

Chart 1 Healthcare equities showed resilience during recent economic downturns

Source: FactSet, all other industry returns from Morningstar, Inc. Past performance is not indicative of future results. It is not possible to invest directly in an index. Y-axis represents the index returns. Biotechnology refers to MSCI World/Biotechnology GR (USD), HC Equip&Supl refers to MSCI World/Health Care Equipment & Supplies GR (USD), HC Providers&Svcs refers to MSCI World/Health Care Providers & Services GR (USD), Pharmaceuticals refers to MSCI World/Pharmaceuticals GR (USD) and Life Sciences Tools & Svcs refers to MSCI World/Life Sciences Tools & Services GR (USD). *Returns during the unwinding of tech-bubble and global financial crisis are not available.


2. What has differentiated our healthcare investment capabilities throughout market ups and downs?

The proprietary fundamental research conducted on a daily basis by seasoned investment professionals with solid medical backgrounds underpins our differentiated investment approach. On average, our portfolio managers have over 30 years of experience spanning large-scale multinational healthcare corporations to global asset management firms. This has laid a solid foundation that helps us make vital investment considerations across the broader healthcare landscape. Slaughter’s educational background in biology, as well as Sylvester’s in biology, neurobiology, and physiology, empower our team with the knowledge base to effectively engage with the medical and scientific communities on the cutting-edge technologies and advancements within healthcare. This, combined with deep industry expertise required for dedicated fundamental research enable us to uncover compelling investment ideas before they are fully appreciated by a broader cohort of market participants.

Adding a layer of scientific research based on fundamental equity analysis

Besides traditional fundamental equity analysis via investment screens and financial modelling, our team devotes energy and passion to building an in-depth and insightful scientific understanding of the healthcare sector. This is based on proprietary fundamental research from:

  • Clinic and hospital visits
  • Company meetings
  • Investor conferences
  • Medical journal reviews
  • Medical conferences
  • Prior holdings

During the research process, our team members act as stewards, proactively attending company meetings and investor conferences, liaising with industry thought leaders, as well as engaging with C-suites and board members (not limited to only companies owned in our portfolio). Our long-standing corporate relationships also enable the team to conduct objective environmental, social, and governance (ESG) analysis of risks and opportunities – driving the positive change that could benefit long-term, value-driven company growth.

The longevity of our on-the-ground research capabilities is instrumental in the bottom-up decision-making process. This includes: i) evaluating end-market size and product demand, ii) identifying product-pipeline strength and conducting competitor product analysis, and iii) assessing the strength of management teams.

Given our passion for the ever-changing healthcare industry, we monitor and digest medical journals and scientific publications from a practitioner’s viewpoint. This approach ensures we are aware of medical advances in pharmaceutical and therapeutic landscapes. As a result, we can avoid over-reliance on secondary or sell-side research, allowing us to independently evaluate markets, uncover hidden ideas, develop in-depth analysis, and make judgements beyond financial numbers and market sentiment. The art of marrying quantitative and qualitative inputs is our main proprietary asset for idea generation – a unique interactive research process that could unlock underappreciated market opportunities.

3. Emerging evidence of adverse health outcomes for patients previously infected with COVID increases the importance of addressing such unmet medical needs. How do you apply your proprietary research approach when identifying alpha-generation opportunities resulting from the long-term impact of the pandemic?

As we highlighted in our 2023 outlook, Manulife IM’s fundamental research process has identified a series of published research studies noting increased morbidity among patients recovering from COVID-19 infections and, as evidenced by, an elevated risk of cardiovascular diseases, diabetes, and central nervous system (CNS) diseases relative to the uninfected population. Coupled with the unmet medical needs for pre-existing conditions, we believe that opportunities abound for experienced investors with keen insights who can identify underappreciated market opportunities and deliver outperformance. Our approach continues to inform how we evaluate investment opportunities across the healthcare universe. To this end, the findings mentioned above relating to structural changes in healthcare (including, but not limited to, long COVID) support the urgency to manage other pre-existing diseases effectively, diagnoses that our research suggests pre-dispose these comorbid patients to higher morbidity and mortality from COVID-19. For example, we continue to look at companies with novel treatments for CNS diseases (depression, Alzheimer’s) and continue to focus on orphan diseases (i.e., those affecting fewer than 200,000 individuals). We see a greater understanding of the genetic causes of these diseases, and those learnings are being applied to novel drugs that could dramatically impact patients. We are also identifying smaller biotech names with significant upside and alpha generation potential, given that these companies’ innovations are in the final phases of clinical development.


Overall, we believe the healthcare sector will remain one of the most defensive segments in any potential economic recession scenario. Additionally, the unprecedented innovation and medical advancements expected in a post-COVID-19 era should provide a fertile opportunity set for market beating growth. Our differentiated research approach, underpinned by experienced and seasoned investment professionals with solid medical backgrounds, allows us to look beyond financial figures and market sentiment to identify companies with potential upside and alpha generation at an earlier stage than others.

We continue to see unprecedented demand among companies with products and services that address all three guiding principles: i) unmet medical needs, ii) underappreciated market opportunities, and iii) the ability to bend the healthcare cost curve.


Download full PDF


  • Hong Kong/Mainland China market update

    Despite the market fall, we believe that the China Q4 2023 GDP growth trend has already been priced into the index, with some bright spots being neglected. Mainland China’s four mega trends (i.e., the “4As”) remain intact as better-than-expected inventory destocking and increased policy measures suggest a potential bottoming of the economy.  

    Read more
  • India’s bond index inclusion: Attracting foreign investment; bolstering its regional position

    Indian government bonds would be included in the JPMorgan Government Bond Index-Emerging Markets (GBI-EM) Global index suite starting in June 2024. We examine the short- and long-term implications of this significant decision for the Indian bond market.

    Read more
  • Transitioning to India’s next stage of growth

    India’s growth agenda is well embedding the primary driver of digitisation that supports the formalisation and reinvestment policies underpinning manufacturing expansion. This is starting to show results with visibly improved capital expenditure and industrial order books, as well as a narrowing current-account deficit and a healthier inflationary picture.

    Read more
See all